HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Hokkaido University Hospital >
Peer-reviewed Journal Articles, etc >

Characteristics of Symptomatic Intracerebral Hemorrhage in Patient Receiving Direct Oral Anticoagulants : Comparison with Warfarin

Creative Commons LicenseCreative Commons Attribution-NonCommercial-NoDerivs 4.0 International

Files in This Item:
JStrokeCerebrovascDis27_1338.pdf304.74 kBPDFView/Open
Please use this identifier to cite or link to this item:http://hdl.handle.net/2115/73805

Title: Characteristics of Symptomatic Intracerebral Hemorrhage in Patient Receiving Direct Oral Anticoagulants : Comparison with Warfarin
Other Titles: Characteristics of ICH with Warfarin and DOAC
Authors: Kawabori, Masahito Browse this author →KAKEN DB
Niiya, Yoshimasa Browse this author
Iwasaki, Motoyuki Browse this author
Mabuchi, Shoji Browse this author
Ozaki, Hiroyuki Browse this author
Matsubara, Koji Browse this author
Houkin, Kiyohiro Browse this author →KAKEN DB
Keywords: DOAC
intracerebral hemorrhage
warfarin
stroke
Issue Date: May-2018
Publisher: Elsevier
Journal Title: Journal of stroke & cerebrovascular diseases
Volume: 27
Issue: 5
Start Page: 1338
End Page: 1342
Publisher DOI: 10.1016/j.jstrokecerebrovasdis.2017.12.020
Abstract: Background: Direct oral coagulants (DOAC) have been shown to decrease the frequency of intracerebral hemorrhage (ICH) compared with warfarin. However, the precise characteristics, such as the size and locations of the hemorrhage, and outcome and onset time of ICH in patient taking DOAC are not fully elucidated. Methods: We retrospectively analyzed the characteristics of symptomatic patients with ICH taking either DOAC or warfarin between January 2012 and December 2015. Results: Out of 400 consecutive patients with ICH, 15 patients were DOAC-ICH and 24 patients were warfarin-ICH. DOAC-ICH was observed in 6 patients with 10 mg of rivaroxaban, 5 patients with 15 mg of rivaroxaban, and 1 patient with 10 mg of apixaban, 5 mg of apixaban, 30 mg of edoxaban, and 60 mg of edoxaban. Prothrombin time was well controlled in most of the warfarin-ICH patients (83.3%). The locations of ICH were similar in both groups; however, median ICH volume was significantly smaller in DOAC-ICH patients than in warfarin-ICH patients (P<.01) and ICH around basal ganglia seemed to show great difference between the groups. DOAC-ICH patients showed better neurological outcome at the time of discharge than warfarin patients (P<.01), and the ratio of good prognosis was significantly higher in the DOAC-ICH patients than in the warfarin-ICH patients (P<.01). The onset of warfarin-ICH was frequently observed in the morning and evening, whereas DOAC-ICH did not show any specific onset time. Conclusions: Patients with DOAC-ICH showed smaller ICH volume and better clinical outcomes than patients with warfarin-ICH, and DOAC-ICH did not show any specific onset peak.
Rights: © 2018. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
http://creativecommons.org/licenses/by-nc-nd/4.0/
Type: article (author version)
URI: http://hdl.handle.net/2115/73805
Appears in Collections:北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 川堀 真人

Export metadata:

OAI-PMH ( junii2 , jpcoar )

MathJax is now OFF:


 

Feedback - Hokkaido University